文献速递肺外科

诱导放化疗(50 Gy)后手术切除治疗IIIA-N2期非小细胞肺癌

Induction Chemoradiotherapy (50 Gy), Followed by Resection, for Stage IIIA-N2 Non-Small Cell Lung Cancer.
PubMed 文献 · Ann Thorac Surg · 2018-06-08

这项II期多机构研究(West Japan Oncology Group 5308L)纳入40例可切除的临床IIIA-N2期非小细胞肺癌患者,评估每周卡铂联合紫杉醇同步胸部放疗(50 Gy,25次)后手术切除及术后巩固化疗的可行性。主要终点为诱导放化疗后完全切除(R0)率,结果为80%,总缓解率58%,2年无进展生存率63%、总生存率75%、无复发生存率62%,30天和90天死亡率均为0%。结论认为该方案可行且有前景。

要点

  • 40例可切除临床IIIA-N2期非小细胞肺癌患者接受诱导放化疗(50 Gy)后手术,R0切除率为80%。
  • 全组完成诱导放化疗,总缓解率58%,50%患者完成包括术后化疗在内的全方案治疗。
  • 中位随访38个月,2年无进展生存率63%、总生存率75%、无复发生存率62%,30天和90天死亡率均为0%。

核心结论

  • 诱导化疗同步放疗(50 Gy)后手术切除是可切除临床IIIA-N2期非小细胞肺癌可行且有前景的治疗选择。

研究设计与样本

  • II期多机构研究(West Japan Oncology Group 5308L),纳入2011年12月至2013年11月40例可切除临床IIIA-N2期非小细胞肺癌患者,N2需病理确认。
  • 患者接受每周卡铂联合紫杉醇化疗同步胸部放疗(50 Gy,25次),无疾病进展者行手术切除,术后接受两周期卡铂联合紫杉醇巩固化疗。
  • 主要终点为诱导放化疗后完全切除(R0)率。

主要发现

  • 全组40例均完成诱导放化疗,总缓解率58%。
  • 32例实现完全切除,R0切除率80%,其中27例接受肺叶切除术。
  • 20例(50%)完成包括术后化疗在内的全方案治疗。
  • 中位随访38个月,2年无进展生存率63%、总生存率75%、无复发生存率62%。
  • 30天和90天死亡率均为0%。

关键数值与推荐

  • R0切除率80%(32/40)。
  • 总缓解率58%。
  • 2年无进展生存率63%、总生存率75%、无复发生存率62%。
  • 30天和90天死亡率均为0%。
  • 50%患者完成全方案治疗。

临床怎么用

  • 原文结论认为诱导化疗同步放疗(50 Gy)后手术切除是可切除临床IIIA-N2期非小细胞肺癌可行且有前景的治疗选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The optimal therapeutic strategy for potentially resectable clinical (c-) stage IIIA-N2 non-small cell lung cancer (NSCLC) remains controversial. This phase II multiinstitutional study (West Japan Oncology Group 5308L) was designed to evaluate the feasibility of induction chemotherapy with concurrent thoracic radiotherapy (50 Gy), followed by resection and postoperative consolidation chemotherapy, in IIIA-N2 NSCLC. METHODS: Patients with resectable c-stage IIIA-N2 were eligible, and pathologic confirmation of N2 disease was mandatory. Patients received chemotherapy consisting of weekly carboplatin plus paclitaxel with concurrent radiotherapy (50 Gy in 25 fractions). Unless disease progression was documented, patients underwent surgical resection, and thereafter received two courses of consolidation chemotherapy with carboplatin plus paclitaxel. The primary end point was the proportion of patients who achieved complete resection after induction chemoradiotherapy (R0 rate). RESULTS: From December 2011 to November 2013, 40 eligible patients were enrolled. All patients completed induction chemoradiotherapy with an overall response rate of 58%, and 32 patients achieved complete resection (R0 rate, 80%) mostly with lobectomy (n = 27). Twenty patients (50%) completed the study treatment, including postoperative chemotherapy. After the median follow-up period of 38 months, the progression-free survival, overall survival, and recurrence-free survival rates at 2 years were 63%, 75%, and 62%, respectively. The 30-day and 90-day mortality were 0%. CONCLUSIONS: Induction chemotherapy with concurrent radiotherapy (50 Gy), followed by resection, was a feasible and promising treatment option for resectable c-stage IIIA-N2 NSCLC.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Tanaka F, Yokomise H, Soejima T, et al. Induction Chemoradiotherapy (50 Gy), Followed by Resection, for Stage IIIA-N2 Non-Small Cell Lung Cancer. Ann Thorac Surg. 2018. PMID: 29890150. doi:10.1016/j.athoracsur.2018.05.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。